Features | Partner Sites | Information | LinkXpress
Sign In
JIB
BioConferenceLive
GLOBETECH PUBLISHING

A MicroRNA Regulates the Mechanism That Prevents Osteoporosis and Bone Metastasis

By BiotechDaily International staff writers
Posted on 07 Jul 2014
Image: Osteoclast, with bone below it, shows typical distinguishing characteristics: a large cell with multiple nuclei and a “foamy” cytosol (Photo courtesy of Wikimedia Commons).
Image: Osteoclast, with bone below it, shows typical distinguishing characteristics: a large cell with multiple nuclei and a “foamy” cytosol (Photo courtesy of Wikimedia Commons).
A study conducted on a mouse model of osteoporosis found that animals with higher than normal levels of the microRNA (miRNA) miR-34a were protected from the syndrome by having increased bone mass and reduced bone breakdown.

MiRNAs are fragments of RNA about 20 nucleotides long that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) have been studying how microRNAs were involved in regulating skeletal biology. To this end, they used mouse models that either underexpressed or overexpressed miR-34a.

They reported in the June 25, 2014, online edition of the journal Nature that miR-34a-overexpressing transgenic mice exhibited lower bone resorption and higher bone mass. Conversely, miR-34a knockout and heterozygous mice exhibited elevated bone resorption and reduced bone mass. At the cellular level it was found that miR-34a or molecules that mimicked the function of miR-34a blocked the development of osteoclasts (cells that cause destruction of bone), which make the bone less dense and prone to fracture. High levels of bone destruction and reduced bone density caused by excessive numbers of osteoclasts are characteristic of osteoporosis.

The investigators pointed out that the mechanisms involved in development of osteoporosis were similar to those that allow certain cancers to metastasize into bone tissue.

“This new finding may lead to the development of miR-34a mimics as a new and better treatment for osteoporosis and cancers that metastasize to the bone,” said senior author Dr. Yihong Wan, assistant professor of pharmacology at the University of Texas Southwestern Medical Center. “Interestingly, the mouse miR-34a is identical to that in humans, which means that our findings may apply to humans as well.”

Related Links:

University of Texas Southwestern Medical Center



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel

Precise Ion Irradiation Dosing Method Developed for Cancer Therapy

Scientists are employing nuclear physics principles to provide more effective approaches to radiotherapy treatment for cancer patients. Radiation therapy using heavy ions is best suitable for cancer patients with tumors that are difficult to access, such as in the brain. These particles scarcely damage the penetrated... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.